Recent news & events:
-
799-P: Gender Differences in Diabetes Distress Comparing Dapagliflozin plus Saxagliptin to Glimepiride When Added to Metformin in Poorly Controlled Type 2 Diabetes
810-P: Patient-reported outcomes in T2D patients inadequately controlled by metformin are more favorable for dapagliflozin plus saxagliptin vs. insulin glargine.
1520-P: Impact of Patient-Centered Factors on Comparative Effectiveness of Initial Therapies in Treatment-Naïve T2D
search:
Follow our blog:
Enter your email address to follow this blog and receive notifications of new posts by email.
799-P: Gender Differences in Diabetes Distress Comparing Dapagliflozin plus Saxagliptin to Glimepiride When Added to Metformin in Poorly Controlled Type 2 Diabetes
MARCIA A. TESTA and DONALD C. SIMONSON, Boston, MA Gender Differences in Diabetes Distress Comparing Dapagliflozin plus Saxagliptin to Glimepiride When Added to Metformin in Poorly Controlled Type 2 Diabetes Author Block: MARCIA A. TESTA, DONALD C. SIMONSON, Boston, MA Distress.
810-P: Patient-reported outcomes in T2D patients inadequately controlled by metformin are more favorable for dapagliflozin plus saxagliptin vs. insulin glargine.
MARCIA A. TESTA, DONALD C. SIMONSON, ELLA EKHOLM, MAXWELL SU, EVA K. JOHNSSON, Boston, MA, Mölndal, Sweden Patient-Reported Outcomes in T2D Patients Inadequately Controlled by Metformin Are More Favorable for Dapagliflozin plus Saxagliptin vs..
1520-P: Impact of Patient-Centered Factors on Comparative Effectiveness of Initial Therapies in Treatment-Naïve T2D
MARCIA A. TESTA, ALEXANDER TURCHIN, MAXWELL SU, DONALD C. SIMONSON, Boston, MA Impact of Patient-Centered Factors on Comparative Effectiveness of Initial Therapies in Treatment-Naïve T2D Author Block: MARCIA A. TESTA, ALEXANDER TURCHIN, MAXWELL SU,.
941-P: Continuous Glucose Monitoring (CGM) Provides Enhanced Sensitivity Compared with Self-Monitored Blood Glucose (SMBG) for Detecting Hypoglycemia during T2D Clinical Trials.
MARCIA A. TESTA, SERGIO SALDIVAR-SALAZAR, MAXWELL SU, JOHANNA F. HAYES, DONALD C. SIMONSON, Boston, MA, Wellesley Hills, MA Continuous Glucose Monitoring (CGM) Provides Enhanced Sensitivity Compared with Self-Monitored Blood Glucose (SMBG) for Detecting Hypoglycemia.
Load more
In 1987, Phase V Technologies, Inc. was founded by the University of Connecticut Research and Development Corporation and named to signify its mission to extend drug development beyond Phase 1 through Phase 4 endpoints and data collection methods. The term “Phase V®” was trademarked as the “fifth phase” of drug development to signify technological advancements in the collection of direct-from-patient assessments and patient-centered outcomes.
Infomation
- Call us: 1-781-237-7737
- Address: 20 Walnut Street, Suite 110, Wellesley Hills, MA 02481
- Need Help: phasev@phasevtechnologiesinc.com
- work time: Mon - Fri : 9.00 am - 5.00 pm
Newsletter
Keep up to date with news from UNSNEC Business. A once a week email with no spam.Recent Posts
Copyright © UNSNEC 2019. All Right Reserved